Krystal Biotech Inc (KRYS)

Currency in USD
152.91
+5.30(+3.59%)
Closed·
Pre Market
152.910.00(0.00%)
·

KRYS Earnings

Latest Release
May 06, 2025
EPS / Forecast
1.20 / 1.46
Revenue / Forecast
88.18M / 99.12M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025--/1.22--/92.24M----Free Sign Up
03/20251.2/1.4688.18M/99.12M-17.81%-11.04%Free Sign Up
12/20241.52/1.2191.14M/91.63M+25.62%-0.53%Free Sign Up
09/20240.91/0.9983.8M/82.94M-8.08%+1.04%Free Sign Up
06/20240.53/0.7870.3M/65.3M-32.05%+7.66%Free Sign Up
03/20240.03/0.3145.25M/48.96M-90.32%-7.58%Free Sign Up
12/20230.3/-0.2942.1M/28.61M+203.45%+47.15%Free Sign Up
09/20232.79/-1.258.6M/6.29M+323.2%+36.72%Free Sign Up
06/2023-1.25/-1.27--/--+1.57%--Free Sign Up
03/2023-1.76/-1.43--/166.67K-23.08%-100%Free Sign Up

All numbers in USD

Krystal Biotech Inc Earnings Call Summary for Q1/2025

  • Krystal Biotech's Q1 2025 EPS of $1.20 missed forecast of $1.46; revenue of $88.18M fell short of $99.12M expectation, causing 14.29% stock drop
  • Net product revenue for VYJUVEC grew 95% YoY; company reported 473% revenue growth over last 12 months despite higher R&D and admin expenses
  • Planned market launches in Germany, France (Q3 2025) and Japan (Q3-Q4 2025); advancing ophthalmology program KB801 for neurotrophic keratitis
  • CEO expressed confidence in continued patient growth driving long-term expansion; executives downplayed competitive threats in Q&A session
  • Analysts suggest 32% upside potential from current levels; stock appears undervalued per InvestingPro's Fair Value analysis
Last Updated: 06/05/2025, 15:24
Read Full Transcript

FAQ

What Is Krystal Biotech's Earnings Per Share (TTM)?

The Krystal Biotech EPS (TTM) is 4.32.

When Is The Next Krystal Biotech Earnings Date?

Krystal Biotech will release its next earnings report on 10 Aug 2025.

What Is Krystal Biotech’s Revenue Forecasts For Upcoming Quarters?

Krystal Biotech’s revenue forecast is 92.24M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.